Revvity, Inc. (NYSE:RVTY) Shares Acquired by Principal Securities Inc.

Principal Securities Inc. lifted its stake in shares of Revvity, Inc. (NYSE:RVTY) by 54.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 598 shares of the company’s stock after purchasing an additional 212 shares during the quarter. Principal Securities Inc.’s holdings in Revvity were worth $67,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the business. JPMorgan Chase & Co. boosted its stake in shares of Revvity by 13.7% during the third quarter. JPMorgan Chase & Co. now owns 344,115 shares of the company’s stock valued at $43,961,000 after acquiring an additional 41,497 shares during the last quarter. Contravisory Investment Management Inc. raised its holdings in shares of Revvity by 1,715.9% during the 4th quarter. Contravisory Investment Management Inc. now owns 69,186 shares of the company’s stock valued at $7,722,000 after buying an additional 65,376 shares during the period. Bretton Capital Management LLC purchased a new stake in Revvity during the 3rd quarter worth approximately $1,405,000. FMR LLC increased its holdings in Revvity by 40.8% during the 3rd quarter. FMR LLC now owns 155,556 shares of the company’s stock worth $19,872,000 after purchasing an additional 45,040 shares during the last quarter. Finally, International Assets Investment Management LLC grew its position in shares of Revvity by 12,674.8% in the 3rd quarter. International Assets Investment Management LLC now owns 13,669 shares of the company’s stock worth $1,746,000 after acquiring an additional 13,562 shares in the last quarter. Hedge funds and other institutional investors own 86.65% of the company’s stock.

Insider Activity at Revvity

In other news, insider Tajinder S. Vohra sold 5,492 shares of the business’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $116.81, for a total value of $641,520.52. Following the sale, the insider now directly owns 19,652 shares in the company, valued at $2,295,550.12. The trade was a 21.84 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Joel S. Goldberg sold 15,170 shares of the business’s stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $126.73, for a total transaction of $1,922,494.10. Following the completion of the sale, the insider now owns 33,400 shares in the company, valued at approximately $4,232,782. This trade represents a 31.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.60% of the stock is currently owned by corporate insiders.

Revvity Stock Down 0.4 %

RVTY opened at $115.00 on Thursday. Revvity, Inc. has a one year low of $97.32 and a one year high of $129.50. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.60 and a quick ratio of 3.03. The firm has a market capitalization of $14.00 billion, a P/E ratio of 52.04, a price-to-earnings-growth ratio of 3.82 and a beta of 1.03. The company has a fifty day moving average price of $116.89 and a 200-day moving average price of $118.57.

Revvity (NYSE:RVTY) last announced its quarterly earnings results on Friday, January 31st. The company reported $1.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.37 by $0.05. Revvity had a net margin of 9.81% and a return on equity of 7.68%. During the same quarter in the previous year, the company earned $1.25 EPS. Equities research analysts expect that Revvity, Inc. will post 4.94 earnings per share for the current fiscal year.

Revvity declared that its board has approved a share repurchase program on Monday, November 4th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the company to purchase up to 6.5% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s management believes its shares are undervalued.

Revvity Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 9th. Stockholders of record on Friday, April 18th will be paid a $0.07 dividend. The ex-dividend date is Thursday, April 17th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.24%. Revvity’s dividend payout ratio (DPR) is presently 12.67%.

Analyst Ratings Changes

RVTY has been the topic of several recent analyst reports. Barclays lifted their target price on Revvity from $135.00 to $140.00 and gave the company an “overweight” rating in a research note on Monday, February 3rd. TD Cowen lifted their price target on Revvity from $141.00 to $144.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Raymond James reiterated an “outperform” rating and set a $145.00 price target (up previously from $140.00) on shares of Revvity in a research note on Monday, February 3rd. KeyCorp increased their target price on Revvity from $132.00 to $145.00 and gave the company an “overweight” rating in a research note on Monday, February 3rd. Finally, Sanford C. Bernstein downgraded Revvity from an “outperform” rating to a “market perform” rating and set a $130.00 price objective for the company. in a research report on Friday, January 10th. Four equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $136.25.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.